clinical trial · NCT04752371
A Study to Evaluate Camoteskimab in Participants With Still's Disease
Adult Onset Still's DiseaseCamoteskimab (CERC-007, AVTX-007, AEVI-007)
brief summary
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
started
Mar 25, 2021
primary completion
May 24, 2022
completion
May 24, 2022
last updated
Aug 23, 2023
official title
A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Camoteskimab in Subjects With Adult Onset Still's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol